Stockreport

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company wi [Read more]